Business ❯ Pharmaceuticals

Biotechnology

Drug Development Acquisitions Mergers and Acquisitions Biosimilars Vaccine Development Cancer Treatment Clinical Trials Partnerships RNA Medicines mRNA Technology Contract Research Organizations Moderna Research and Development Gene Editing Clinical Development Market Trends Clinical Research Contract Manufacturing Artificial Intelligence Collaboration Capacity Building Healthcare Partnerships Fermentation Technology Market Access Vaccine Production RNA Therapeutics Cell Therapy Drug Discovery Cancer Therapies Clinical-stage Companies AI Collaboration Obesity Drugs Market Competition Company Relations Startups Biomanufacturing Therapies Public Companies Prevacus BioNTech Regulatory Approval Market Impact Emerging Companies Diagnostics Royalty Agreements Medical Products Logistics Gene Therapy Active Ingredients Amylyx Pharmaceuticals, Inc. Biopharmaceutical Companies

Amgen Buys Oxford Spinout Dark Blue Therapeutics for Up to $840 Million

The purchase brings a first-in-class MLLT1/3 protein degrader into Amgen’s oncology research.

Zymeworks and BeOne Say Phase 3 Zanidatamab Regimens Top Two Years’ Survival in First-Line HER2+ GEA

Sanofi, Dren Bio Set Autoimmune Collaboration Worth Up to $1.7 Billion With $100 Million Upfront

Lead-Plaintiff Deadline Nears in MoonLake Securities Suits After SLK Trial Miss

Mirum to Acquire Bluejay Therapeutics in Up to $820 Million Deal for Hepatitis D Drug

Telix Securities Suit Advances as Investor Firms Push Lead-Plaintiff Bids Before Jan. 9 Deadline

Regeneron, Tessera Strike $150 Million Gene-Editing Pact for Alpha‑1 Antitrypsin Deficiency

Pfizer’s mRNA Flu Shot Tops Standard Vaccine in Large Phase 3 Trial

European Commission Authorizes Gobivaz, First Simponi Biosimilar, Across the EEA

Nuvalent Reports 31% ORR in Pretreated, 86% in Untreated ALK+ NSCLC With Neladalkib

Avantor Faces Shareholder Class Action Over Competition Disclosures as Lead-Plaintiff Deadline Nears

Metsera Backs Pfizer’s $10 Billion Deal, Citing Regulatory Risks in Novo Bid

Vertex Tops Q3 Estimates on CF Franchise as New Drugs Miss and Outlook Edges Higher

Biogen Licenses Vanqua’s Preclinical C5aR1 Drug in Deal Worth Up to $1.06 Billion

Takeda Strikes $11 Billion-Plus Oncology Deal With Innovent, Pays $1.2 Billion Upfront

Rani Therapeutics and Chugai Sign Oral Biologics Collaboration Worth Up to $1.085 Billion

Novo Nordisk Licenses Omeros’ MASP-3 Drug in Deal Worth Up to $2.1 Billion

AstraZeneca Licenses Algen’s AI-Guided CRISPR Discoveries in Deal Worth Up to $555 Million

Pfizer to Buy Metsera in Up to $7.3 Billion Obesity Bet

Roche to Acquire 89bio in Deal Worth Up to $3.5 Billion